

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome
E-mail

ROMITI ADRIANA
adriana.romiti@uniroma1.it

Nazionalità

Italiana

ESPERIENZA LAVORATIVA

- 2013-2014: assegno di ricerca II Facoltà di Medicina, 'Sapienza' Università degli Studi di Roma
- 2012-2013: assegno di ricerca II Facoltà di Medicina, 'Sapienza' Università degli Studi di Roma
- 2003-2011: Dirigente medico, UOC di Oncologia, Azienda Ospedaliera Sant'Andrea, <http://www.ospedalesantandrea.it/> - Roma
- 1990-2003 dirigente medico, Istituto Nazionale per la Ricerca sul Cancro (IRCCS) - <http://www.istge.it/> - GENOVA sezione periferica di "Biotecnologie", Dipartimento di Medicina Sperimentale e Patologia, Università di Roma "La Sapienza"

ISTRUZIONE E FORMAZIONE

- 31 Ottobre 1994: Diploma di specializzazione in Oncologia Clinica, "Sapienza" Università di Roma Voto : 70/70 e lode
- 18 Luglio 1989: Diploma di Specializzazione in Gastroenterologia ed Endoscopia Digestiva, "Sapienza" Università di Roma, Voto: 70/70 e lode
- 4 Novembre 1985: Laurea in Medicina e Chirurgia, "Sapienza", Università di Roma, Voto: 110/110 e lode

MADRELINGUA

ITALIANO

ALTRE LINGUA

INGLESE: COUNCIL OF EUROPE LEVEL B2

PRINCIPALI PUBBLICAZIONI

1. Hepatic encephalopathy: hypothesis and controversies. Capocaccia L, Riggio O, Romiti A et al. **Ital. J. Gastroenterol.** 19: 337-338, 1987.
2. Optimal nutritional indices in chronic liver disease. Merli M, Romiti A, Riggio O et al. **J. Par. Ent. Nutr.** 11, 4: 130-134, 1987.
3. The effect of oral BCAA supplement on diurnal variations in plasma amino acid concentrations in cirrhotic patients. Merli M, Riggio O, Romiti A, et al. **Nutrition** 4, 5: 351-356, 1988
4. Circadian periodicity of plasma amino acid variations in cirrhotic patients. Pieche U, Riggio O, Romiti A et al. **Ital. J. Gastroenterol.** 21: 146-150, 1989
5. Basal energy production rate and substrate use in stable cirrhotic patients. Merli M, Riggio O, Romiti A et al. **Hepatology** 12, 1: 106-112, 1990
6. Malabsorption and nutritional abnormalities in patients with liver cirrhosis. Romiti A, Merli M, Martorano M et al. **Ital. J. Gastroenterol.** 22: 118-123, 1990
7. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. Riggio O, Varriale M, Romiti A et al. **J. Clin. Gastroenterol.** 12, 4: 433-436, 1990
8. Resistance to insulin suppression of plasma free fatty acids in liver cirrhosis. Merli M, Leonetti F, Romiti A et al. **J. Endocrinol. Invest.** 13: 787-795, 1990.
9. Early post prandial energy expenditure and macronutrient use after mixed meal in cirrhotic patients. Riggio O, Merli M, Romiti A, et al. **JPEN** 16,5: 445-450, 1992
10. Nutritional status in cirrhosis _ Italian cooperative project on nutrition. **J. Hepatology** 21:317-325, 1994
11. Analysis of p53 expression in precancerous and malignant gastric mucosa. A Romiti, A Moretti, A Vecchione, R Muraro, ML Feudi, V Rinaldi, R Mancini, C Valli, A Mozzicafreddo, L Frati and S Tomao. **Oncology Reports** 5: 109-113, 1998
12. Onset of Hepatocellular carcinoma in a non cirrhotic patient affected with haemochromatosis. S Tomao, A Romiti, A Mozzicafreddo, M Raffaele, A Zullo, A Antonaci. **Oncology Reports** 5(3) 723-5, 1998
13. Gastric pathology in patients with variable immunodeficiency. A Zullo, A Romiti, V Rinaldi, A Vecchione, S Tomao, F Aiuti, L Frati, G Luzi. **Gut** 45, 1: 77-81; 1999
14. 5-Fluorouracil plus folinic acid with or without ifosfamide in advanced colorectal cancer: a phase II randomized trial. A Sdrobolini, A Contu, B Massidda, S Gasperoni, F Recchia, A Iannelli, S Tomao, A Romiti et al. **Tumori**, 86: 195-198, 2000
15. Gastric epithelial cell proliferation in patients with liver cirrhosis. Zullo A, Romiti A, Rinaldi V, Vecchione A, Hassan C, Winn S, Tomao S, Attili AF. **Dig Dis Sci.** 2001 Mar;46(3):550-4.
16. A Phase II study of Gemcitabine and Tamoxifen in advanced pancreatic Cancer. S Tomao, A Romiti, B Massidda, M T Ionta,

- A Farris, A Zullo, A Brescia, L Santuari, F Tomao and L Frati. **Anticancer Research** 22 (4):2361-2364, 2002
17. Tolerability of Raltitrexed (Tomudex) in elderly patients with colorectal cancer. A Romiti, G Tonini, D Santini, M Di Seri, R Masciangelo, S Mezi, A Veri, L Santuari, B Vincenzi, A Brescia, P Marchei, L Frati, S Tomao. **Anticancer Res** 22 (5): 3071-6, 2002
 18. Gastric cancer prevalence in patients with liver cirrhosis. A Zullo, A Romiti, S Tomao, C Hassan, V Rinaldi, M Giustini, S Morini, F Taggi. **Eur J Cancer Prev** 12 (3):179-82, 2003
 19. Is there a benefit by the sequenze anastrozole-formestane for postmenopausal metastatic breast cancer women? Carlini P, Ferretti G, Di Cosimo S, Coltella E, Tonacella R, Romiti A, Tomao S, Frassoldati A, Papaldo P, Fabi A, Ruggeri EM, Cognetti F. **J Steroid Biochem Mol Biol** 86 (1): 107-9, 2003
 20. Adjuvant systemic therapies in women with breast cancer. an audit on clinical Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy Drug Utilization Review Team in Oncology (DURTO) practice in Italy. Drug Utilization Review Team in Oncology. **Annals of Oncology** 14: 843-848, 2003 PMID: 12796020
 21. Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy. Drug Utilization Review Team in Oncology (DURTO). **Supportive Care in Cancer** 11: 785-789, 2003 PMID: 14579136
 22. Studio prospettico osservazionale sulla presenza di "fatigue" a distanza di tempo dal trattamento primario in donne con storia di neoplasia mammaria: studio preliminare. Gualandi Raffaella, Rocci Laura, Vincenzi Bruno, Romiti Adriana, Tomao Silverio, Tonini Giuseppe, et al. **International nursing perspectives** 2003;3(3):137-144.
 23. Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: antiemetic prescriptions and incidence of emesis. Italian Group of Antiemetic Research. **Tumori** 90, (1): 103 - 106, 2004
 24. Alteration of E-Cadherin expression in gastric mucosa: role of intestinal metaplasia and helicobacter pylori infection. Zullo A, Romiti A, Borrini F, Hassan C, Stella F, Sarcina I, Martini ME, Tomao S, Morini S, Mingazzini P. **Anticancer Research** 2004; 24 (3a): 1603-7
 25. Relationship between β -catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia. Romiti A, Zullo A, Borrini F, Sarcina I, Hassan C, Winn s, Tomao S, Vecchione A, Morini S, Mingazzini P. **World J Gastroenterol** 11 (28): 4400-3, 2005
 26. Gastric mucosa alterations in first-degree relatives of gastric cancer patients. A Romiti, A Zullo, S Tomao, C Hassan, I Sarcina, V De Francesco, E Ierardi, F Tomao, A Vecchione, S Morini. **Anticancer Research** 25 (3C): 2567- 2572, 2005
 27. Modulation of 5-fluorouravil as adjuvant chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomized,

- phase III study. S De Placido, M Lopez, C Carlomagno et al. **Br J Cancer** 93, 896-904, 2005
28. Long-term survival in metastatic pancreatic cancer. A case report and Review of the literature. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, Spalletta B, Eramo A, Hassan C, Tomao S. **JOP**. 2006; 7:486-91.
 29. Gastric epithelial cell proliferation and ras oncogene p21 expression in first-degree relatives of gastric cancer patients: a case-control study. Zullo A, Hassan C, Marangi S, Burattini O, Romiti A, De Francesco V, Panella C, Morini S, Ierardi E. **Eur J Gastroenterol Hepatol**. 2006;18:921-6.
 30. A Phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. Tomao S, Romiti A, Tomao F, Di Seri M, Caprio G, Spinelli GP, Terzoli E, Frati L. **BMC Cancer** 2006; 24; 6:137.
 31. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. Di Costanzo F, Gasperoni S, Manzione L, Bisogni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioli F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L et al. **J Natl Cancer Inst**. 2008;100:388-98.
 32. Duodenobronchial fistula arising from a necrotizing liver metastases of right colon cancer after systemic chemotherapy. Mercantini P, Virgilio E, Balducci G, Addario Chieco P, Romiti A, Di Rocco R, Ziparo V. **The American Surgeon** 2010; 76: 1434-1435.
 33. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, Piloizzi E, Romiti A, Cavallini M, Ziparo V. **World J Surg Oncol**. 2011;9:13
 34. Tumors of ampulla of Vater: A case series and review of chemotherapy options. Romiti A, Barucca V, Zullo A, Sarcina I, Di Rocco R, D'Antonio C, Latorre M, Marchetti P. **World J Gastrointest Oncol**. 2012; 4:60-7.
 35. Follow-up of intestinal metaplasia in the stomach: When, how and why. Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, Campo SM, Tomao S. **World J Gastrointest Oncol**. 2012;4:30-6.
 36. Simultaneous intraductal papillary neoplasms of the bile duct and pancreas treated with chemoradiotherapy. Valente R, Capurso G, Pierantognetti P, Iannicelli E, Piciucchi M, Romiti A, Mercantini P, Larghi A, Federici GF, Barucca V, Osti MF, Di Giulio E, Ziparo V, Delle Fave G. **World J Gastrointest Oncol**. 2012; 4:22-5.
 37. Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. Romiti A, D'Antonio C, Zullo A,

- Sarcina I, Di Rocco R Barucca V, Durante V, Marchetti P. **J Gastrointest Cancer**. 2012; 43:396-404
38. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab. D'Antonio C, Viterbo A, Romiti A, Enrici MM, Lauro S, Marchetti P. **J Thorac Oncol**. 2012;7:468-9.
 39. Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma. Romiti A, Di Rocco R, Milione M, Ruco L, Ziparo V, Zullo A, Duranti E, Sarcina I, Barucca V, D'Antonio C, Marchetti P. **Anticancer Res**. 2012; 32:115-9.
 40. Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. Jasmine Passerini, Adriana Romiti, Chiara D'Antonio, Vittoria Mastromarino, Paolo Marchetti, Massimo Volpe and Elena Conti. **Current Signal Transduction Therapy** 2012; 7: 265-288.
 41. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Di Seri M, Longo F, Mottolese M, Giannarelli D, Ruco L, Romiti A, Barucca V, Adua D, Tomao S. **Future Oncology** 2012; 8, p. 1193-1197.
 42. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P, Romiti A, Barucca V, Giannini G, Bianchi L, Tomao S. **Onco Targets Ther** 2013; 29 (6):1761-9.
 43. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, Marchetti P. **Cancer Chemother Pharmacol** 2013; 72(1):13-33.
 44. Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. Conti E, Romiti A, Musumeci MB, Passerini J, Zezza L, Mastromarino V, D'Antonio C, Marchetti P, Paneni F, Autore C, Volpe M. **Int J Cardiol** 2013; 167(6):2421-9
 45. Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? Lorenzon L, Mercantini P, Ferri M, La Torre M, Sparagna A, Balducci G, Tarantino G, Romiti A, Pillozzi E, Ziparo V **Scientific World Journal** 2013; 24:196541.
 46. Helicobacter pylori infection and gastroesophageal cancer: unveiling a Hamletic dilemma. Zullo A, Hassan C, Francesco VD, Manta R, Romiti A, Gatta L. **Ann Gastroenterol** 2014; 27(4):291-293.
 47. Circulating tumor cells count predicts survival in colorectal cancer patients. Romiti A, Raffa S, Di Rocco R, Roberto M,

- Milano A, Zullo A, Leone L, Ranieri D, Mazzetta F, Medda E, Sarcina I, Barucca V, D'Antonio C, Durante V, Ferri M, Torrissi MR, Marchetti P **J Gastrointestin Liver Dis** 2014; 23(3):279-84.
48. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, Tomao L, Romiti A, Lo Russo G, Tomao S. **Tumour Biol** 2014; 35(7):6195-206.
49. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D'Antonio C, Durante V, Milano A, Falcone R, Di Rocco R, Righini R, Marchetti P. **Med Oncol**. 2015 Mar;32(3):54.